Related Experiment Videos
Lifetime treatment costs of beta-thalassaemia major
Insights
The lifetime cost of treating beta-thalassaemia major, a severe genetic disorder, is substantial. This study estimates the health service costs to aid in healthcare planning and resource allocation for beta-thalassaemia major patients.
Area of Science:
- Medical Genetics
- Health Economics
Background:
- Beta-thalassaemia major is a severe genetic disorder associated with significant morbidity and mortality.
- Despite its rarity, affecting approximately 600 individuals in the UK, the treatment is intensive and resource-demanding.
Purpose of the Study:
- To calculate the lifetime cost of treatment services for beta-thalassaemia major patients.
- To provide data for health care planning and resource allocation decisions.
- To inform the decision-making process for antenatal screening programs.
Main Methods:
- Development of a cost model incorporating data from various sources.
- Estimation of undiscounted and discounted lifetime treatment costs.
- Sensitivity analyses to determine the range of discounted costs.
Main Results:
- The estimated undiscounted lifetime cost of treating a beta-thalassaemia major patient is £803,002.
- The discounted lifetime cost (at 6%) is estimated at £219,068.
- Sensitivity analyses showed discounted costs ranging from approximately £188,000 to £226,000.
Conclusions:
- The lifetime treatment of beta-thalassaemia major represents a significant cost to the health service.
- This cost analysis can guide healthcare providers in resource allocation and planning for beta-thalassaemia major services.
- Findings support the economic rationale for implementing antenatal screening programs.
Abstract:
Beta-thalassaemia major is a serious genetic disorder, which results in a considerable increase in both acute and chronic morbidity, and mortality. Although beta-thalassaemia major is a rare disease affecting approximately 600 people in the UK, treatment is intensive and predictions of the costs incurred may aid health care planning. In this report, the cost to the health service of providing treatment services for beta-thalassaemia major patients, over the course of a lifetime, is calculated in order to assist resource allocation decisions. A cost model was developed, incorporating data from disparate sources. The undiscounted lifetime cost of treating a beta-thalassaemia major patient was estimated to be pound 803,002, although when the costs were discounted at a rate of 6%, the lifetime cost was reduced to pound 219,068. Within sensitivity analyses, the discounted cost ranged from approximately pound 188,000 to pound 226,000. This report may act as a guide to those involved in the planning of health care provision with regard to the resources required to treat beta-thalassaemia major patients. Such information may also be incorporated into the decision-making process for the provision of antenatal screening programmes for beta-thalassaemia major.